Colorectal Cancer, Colorectal Carcinoma, Microsatellite Instability High, Microsatellite Instability Low, Microsatellite Instability-High
Conditions
Keywords
Colorectal cancer, Prognostic factor, Microsatellite instability, Prognosis, Survival
Brief summary
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters.
Detailed description
According to Global Cancer Statistics, higher than 1.9 million new cases of colorectal cancer (CRC) and 935,000 deaths are estimated to occur in 2020, representing about one in 10 cancer cases and deaths. Overall, it ranks third in colorectal incidence but second in mortality. In CRC evolution, the acquisition of genomic instability is a critical point, and there are at least two different pathways in the pathogenesis of CRC: the chromosomal instability (CIN) pathway (85%) and the microsatellite instability (MSI) pathway (15%). Microsatellite instability (MSI) is a phenotype that occurs due to a malfunction in the DNA repair mechanism and is seen in approximately 15% of colorectal cancers (CRCs). CRCs with MSI have different clinical features, such as a tendency to settle in the proximal colon, poor differentiation, and more lymphocytic infiltration in the tumor. It has been shown that CRCs with MSI have a better prognosis and respond differently to chemotherapy than CRCs with microsatellite stable (MSS). We aimed to evaluate the different histopathological features of tumors with MSI compared to MSS in patients who underwent surgery for colorectal cancer. We also planned to determine how MSI affects prognostic parameters such as mortality rate, recurrence, disease-free survival, cancer-specific survival, and overall survival.
Interventions
DIAGNOSTIC_TESTMicrosatellite instability analysis
Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
Sponsors
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
* Colorectal surgery patients * Complete follow-up information
Exclusion criteria
* Whose MSI status was not studied in the pathology material * Missing follow-up information * Colorectal resection for non-neoplastic diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Five years | Overall survival is defined as the time interval from the time of primary operation to the date of all-cause death or the last follow-up. |
| Disease-Free Survival | Five years | Disease-Free Survival is defined as the time interval from the time of primary operation to disease recurrence or death. |
Countries
Turkey (Türkiye)
Outcome results
None listed